42 results about "In vitro stimulation" patented technology

A method including in vitro stimulating a core cell population (CCP) of at least 5 million cells that have a density of less than 1.072 g / ml, and at least 1.5% of which are CD34+CD45− / dim, to differentiate into a neural progenitor / precursor cell population (NPCP). Other embodiments are also described.

The invention discloses a preparation method and application of a magnetic nano microcarrier for wrapping a tumor cell membrane. The method is based on the tumor cell membrane, and the surface of a ferroferric oxide nano particle modified by silicon dioxide is wrapped with the cell membrane derived from a tumor cell through a membrane-nano coextrusion and centrifugation method, so that the Fe3O4@SiO2 magnetic nano microcarrier (CMNPs) wrapped with the tumor cell membrane is formed. The magnetic nano microcarrier contains a tumor cell membrane surface antigen, has superparamagnetism, and can beenriched and purified by a magnetic field, so that the magnetic nano microcarrier can stimulate activation of immune cells in vitro or is injected into a body to be captured by macrophages to improvea tumor specific antigen, and the anti-tumor effect is enhanced. The preparation method of the microcarrier based on the cell membrane has the advantages of simplicity and easiness in operation, lowcost, wide application and the like.

The invention belongs to the immunology field, in particular to a proteantigen molecule-Japanese blood fluke heat shock protein 60KDa (SjHSP60) which is derived from a blood fluke and is capable of increasing CD4 + CD25 + Foxp3 + regulatory T cells and application thereof. The SjHSP60 has a full-length amino acid sequence as shown in SEQ.ID.NO.1, has a series of identical or highly similar cross-reactive T cell epitopes with HSP60 infected by a host. After being used for mouse in vivo immunization or in vitro stimulus to mouse spleen and lymph gland cells, the SjHSP60 can obviously increase CD4 + CD25 + Foxp3 + Tregs. In practical application, the SjHSP60 can effectively relieve inflammatory symptoms and immunopathological effects caused by arthritis, thereby having wide prospects in the aspects of immunological suppression inducement and treatment of immunological diseases.

The invention belongs to the technical field of biology, and particularly relates to screening and identification of antigen epitope polypeptides. The invention discloses screening, identification and application of a series of rabies virus glycoprotein and nucleoprotein antigen epitope polypeptides. The rabies virus glycoprotein and nucleoprotein are predicted by biological information means to obtain the candidate epitope polypeptides; and a lymphopoiesis experiment, ELISPOT experiment and a stream-type cell method are utilized to carry out in-vitro experimental verification on the subsequent epitope polypeptides to obtain the four rabies virus protein antigen epitope polypeptides. The invention is characterized in that the antigen epitope polypeptides respectively comprise a Th epitope and a CTL epitope, can stimulate the lymphopoiesis of the vaccine-immunized mouse in vitro and induce the cells to secrete related cell factors, and have the functions of killing virus-infected cells and stimulating the generation of the antibody. The invention can be used for developing rabies virus epitope vaccines and detecting the vaccine effect, and has important value for developing and producing immunologic function detection kits for rabies virus vaccines.

The invention discloses an in-vitro test stimulator, and belongs to the technical field of implanted medical instruments. The in-vitro test stimulator is mainly used for nervous electric stimulation therapy test. The double-channel pulse output in-vitro test stimulator with a user interface can output accurate parameter adjustable electrical stimulation pulse, and is used for treatment test or short-term electric stimulation therapy experience of patients in implanted nerve stimulator operation. The test stimulator is characterized in that the test stimulator adopts integrated structural design, and mainly comprises a shell, a toggle switch, a film key, a display screen, a battery, a printed circuit board and the like. The test stimulator is small and simple; through the key and the switch, pulse parameters and test electrode load impedance can be adjusted and the polarity of an electrode contact can be set, so the test stimulator is intuitive and convenient to operate; and through the design of self-locking function and error operation prevention, error operation of the patients in use can be effectively prevented, and the test stimulator is safe and reliable. The test stimulator can be widely applied to test assessment and experience of electric stimulation therapy.

The invention discloses an immune adjuvant of a foot-and-mouth disease vaccine and application of the immune adjuvant, and belongs to the field of biological vaccines. The immune adjuvant is a 3D protein fragment of foot-and-mouth disease viruses. Experiments prove that after the expressed 3D protein fragment is compatible with antigens, animals are immunized, the immunogenicity of multi-epitope antigens can be enhanced, and high-level protective neutralizing antibodies are produced. In vitro stimulation shows that after the 3D protein fragment of the foot-and-mouth disease viruses is separately adopted or compatible with the multi-epitope antigens, lymphocyte proliferation response can be produced, namely the immune adjuvant can be used for enhancing immune response, distinguishing infection and immunizing the animals and is a good immune stimulant and a vaccine molecular marker.

The invention relates to a medical suture friction testing apparatus. The apparatus comprises an assembly for testing the friction performance of a medical suture when the medical suture penetrates tissues, and an assembly for testing the friction performance between medical sutures. The assembly for testing the friction performance of a medical suture penetrating tissues stimulates the friction performance between the medical suture and all tissues when the medical suture penetrates human tissues, and the assembly for testing the friction performance between medical sutures stimulates the friction assembly between the medical sutures in the knotting process of the medical suture. The two assemblies can be arranged in a multifunctional fiber strength and elongation tester to replace a lower clamping head of the tester in order to carry out relevant friction performance test. The invention also discloses a corresponding medical suture friction testing method. The friction testing apparatus has the advantages of simple structure, convenient operation, and objective and real result. The apparatus and the method fill up a blank in the quantitative characterization of present in-vitro stimulation of the friction performance of the medical suture, and provide scientific bases for the improvement of the structure of the medical suture.

The invention provides a stimulation device of time-phase characteristics of coronary artery blood flow, which relates to the technical field of in vitro stimulation experiments and aims at solving the technical problems that the existing hemodynamic parameters of clinical patients and experimental animals have randomness and the blood flow is difficult to be measured. The device comprises a fluid line system which consists of a cardiac pump, an accumulator, a fluid flow loop and a fluid storage tank which are sequentially and circularly connected, and a motor which drives the cardiac pump to move; and the device is characterized in that: the fluid flow loop comprises a two- position three-way valve, a diastolic branch and a systolic branch; one end of the diastolic branch and the systolic branch is respectively connected with two outlets of the two-position three-way valve, and the other end is connected with the fluid storage tank, a common inlet of the two-position three-way valve is connected with the accumulator, and the two-position three-way valve is driven by the motor to cause the common inlet to be communicated with the diastolic branch and the systolic branch along with the alternation of the diastole and the systole of the cardiac pump, and fluid resistance of the systolic branch is greater than that of the diastolic branch. By adopting the stimulation device of the invention, the time-phase characteristics of the coronary artery blood flow can be reproduced.

The invention discloses a wireless program-controlled illumination system used for cell high-throughput research of optogenetics. The system comprises an upper computer and control software, a wireless communication module, a lower computer central processor, a lower computer register chip set, a lower computer light emitting diode group and a constant-voltage direct-current power supply. The device provided by the invention is used for the research for the optogenetics signal channel of the in-vitro large-scale culture of cells, especially the research for drug molecule screening relevant to the signal channel, the problem that in the current relevant researches, the devices for realizing high-throughput, multi-intensity, long-time and multi-factor illumination in-vitro stimulation are not available is solved, and the accuracy and experiment efficiency of the light stimulation system in the optogenetics research are effectively improved. In addition, the cell culture light activating conditions acquired based on the system provided by the invention, such as the illumination intensity and the light activating time, have wide application prospects for the optogenetics research of the cells in the future.

The invention relates to a cells separating technology, and provides a tumor infiltrating lymphocytes separation method. The method is characterized by adding tumor tissue masses in a trypsin-EDTA solution for immersion and incubation, fully digesting and dispersing the tumor tissue masses; separating and collecting single cell and being resuspended by the trypsin-EDTA solution for multitime density gradient centrifugation, incubating and separating by an erythrocyte lysate, using calf serum-containing PBS buffer or resuspending to obtain the dissolved tumor infiltrating lymphocytes. In the invention, an enzymatic digestion method and a machinery method are combined for dual separating the enzymatic digestion with high efficiency, compared with the machinery method or the enzymatic digestion method, the survival rate of the obtained tumor infiltrating lymphocytes is high, and the method is simple and easy to operate. The obtained tumor infiltrating lymphocytes can be massively propagated through in vitro stimulation of interleukin 2 (1L-2), have antineoplastic activity with specialty and high efficiency, and provides powerful basis and new approach for treating tumour.

The present invention relates to the field of therapeutic immunization, specifically with the use of a novel hepatitis B virus (HBV) antigen formulation for cell stimulation. The formulation is formed by HBV surface antigen (HBsAg) and nucleocapsid antigen (HBcAg) precipitates in suspension. The formulation contains said antigens as precipitates in suspension as particles with sizes less than 500 nm and greater than 500 nm, in a mixture in which the proportion between the particles of the sizes mentioned is between 50% - 50% and 80% - 20%, respectively. The selection of a range of particle sizes allows the levels of stimulation of various cell types to be maximized. In addition, a description is given of a method for cell stimulation using said formulation and the subsequent passive immunization of patients with chronic hepatitis B, based on the maximum in vivo or in vitro stimulation of heterologous or autologous cells (dendritic cells, B cells and macrophages). The cells stimulated with this formulation are transferred to patients with a chronic HBV infection.

The invention discloses a tumor composite antigen, a dendritic cell multivalent vaccine and application of the tumor composite antigen and the dendritic cell multivalent vaccine. Dendritic cells of a patient are stimulated in vitro, multiple tumor cell lysates with super immunogenicity aiming at different EBV related tumors are loaded, mature dendritic cells are formed under induction of multiple cell factors and specific agonists, a complete DC vaccine with corresponding cancer antigens is formed, the DC vaccine is transfused back to a human body to activate an immune system, and the EBV related tumors are subjected to tumor immunogenicity. Natural immunity (such as induction of NK cells) is stimulated, lymphocytes are stimulated to generate acquired immune response, cytotoxic T cells are generated to kill cancer cells, and the cancer cells are accurately killed together; compared with radiotherapy and chemotherapy, the composition is particularly safe and almost has no side effect; and the dendritic cell vaccine has a preparation cycle of about 1 week, and is short in time and low in cost.

This invention provides cells and methods for stimulating proliferation and migration of endogenous and exogenous mammalian stem cells in vivo and in vitro. The invention provides reagents and methods for efficiently proliferating mammalian stem cells in an animal in need thereof and producing stem cells that can be re-introduced into an animal in need thereof to alleviate neurological and corporal disorders.

pZerotgCMV, an Ad-5-based expression vector in current use for gene transfer stimulates lipogenic enzymes within HepG2 cells (human hepatic carcinoma cells) and primary rat hepatocytes in vitro. Evidence indicates increased lipid accumulation in infected cells compared to uninfected cells. Therefore, inactivation of the E4 ORF1 gene or E4 gene cluster whether by replacement, removal, mutation, or use of antisense RNA encoded by the Ad-5 genome may prevent activation of lipogenic genes and subsequent lipid accumulation. Removal of just the E4 gene from pZerotgCMV may prevent both replication and stimulation of lipogenic enzymes.

The invention relates to the field of immune medicine, in particular to a rhamnose lactobacillus Pr2 peptide and a coding gene, a separation method and application thereof. The rhamnose lactobacillus Pr2 peptide has an amino acid sequence shown as SEQ No.1. The rhamnose lactobacillus sourced Pr2 peptide has the capability of producing Tregs through in-vitro stimulus. In addition, the Tregs can produce antigenic specificity Tregs when being exposed under Pr2 and antigen. The antigenic specificity Tregs can be activated when being exposed under specificity antigen. The activated antigenic specificity Tregs can release functional molecules such as IL-10, TGF- beta and FasL. The adoptive transfer of the antigenic specificity Tregs to a sensitized mouse or the giving of the Pr2 and specificityantigen to the sensitized mouse can obviously inhibit the antigenic specificity Th2 reaction and anaphylactic reaction in the body of the mouse. Therefore, the method has the potential application value in the treatment of food allergy diseases.

The invention provides compositions and methods for promoting stem cell and / or progenitor cell proliferation and / or differentiation. The provided compositions may be useful in treating a disease or condition that is related to mucosal barrier function, e.g., wound healing, treating skin conditions (e.g., atopic dermatitis, psoriasis, bed sores, or condition related to the aging of skin), treatinga lung disorders (e.g., asthma), a condition related to improving mucosal barrier function, and / or treating injury to GI mucosa in a subject in need thereof. The invention also provides methods for promoting the proliferation and / or differentiation of stem cells and / or the progenitor cells in a subject in need of such treatment by administering a composition. The ability to stimulate the proliferation and / or differentiation of stem cells and / or the progenitor cells in vivo, ex vivo and / or in vitro provides tremendous benefit. The compositions can be used to increase stem cell populations in vivo, ex vivo and / or in vitro. Stem cell transplantation provides treatments and / or cures of many disease states, degeneration and / or injury.

The invention provides a method for regulating the polarization state of macrophages. The method comprises the step of activating cholinergic anti-inflammatory pathways of the macrophages by adoptingcholinergic anti-inflammatory pathway agonists and / or vagus nerve electrical stimulation signals. According to the method in the invention, the cholinergic anti-inflammatory pathway agonists are adopted to stimulate the macrophages in vitro; or the electrical stimulation signals are adopted to stimulate vagus nerves in vivo; therefore, the cholinergic anti-inflammatory pathways are activated; polarization of M1 type macrophages is inhibited; polarization of M2 type macrophages is promoted; a regulating effect on macrophage polarization types is achieved; and the method has the important significance in the aspects of specifically regulating the functions of the polarized macrophages and diseases caused by the polarized macrophages.

Disclosed are methods of obtaining a cell population enriched for T cells having antigenic specificity for a cancer-specific mutation using in vitro stimulation of memory T cells. Also disclosed are related methods of isolating a T cell receptor (TCR), populations of cells, TCRs or antigen-binding portions thereof, pharmaceutical compositions, and methods of treating or preventing cancer.

The invention belongs to the technical field of inhibition of hypoxia spermatogenesis reduction, and discloses a detection method for inhibition of hypoxia spermatogenesis reduction of DR5 by VHA. VHAgene knockout mice and C57BL / 6 mice are used as research objects, and a hypoxia spermatogenesis reduction model is constructed through hypoxia induction. A seminiferous tubule seminiferous cell of anexperimental mouse is separated to serve as a research object. Hypoxic in-vitro stimulation is conducted, and the regulating effect and the molecular mechanism of VHA for inhibiting seminiferous cellexpression DR5 are verified through western blot, immunocytochemistry and qPCR technologies. According to the detection method for inhibiting DR5 spermatogenesis reduction under oxygen deficit by VHA, which is provided by the invention, the effect of hypoxic inhibition of VHA in hypoxic spermatogenesis reduction and the molecular mechanism of hypoxic inhibition of VHA in inhibition of DR5 expression are clarified, and a necessary theoretical basis and a new treatment strategy are provided for treatment of hypoxic spermatogenesis reduction.

The invention discloses a hepatoma AFP (alpha-fetoprotein) specific artificial antigen-presenting cell inducing reagent kit, belongs to the technical field of cytobiology and solves the problems of the prior art that in-vitro amplification of DC cells is difficult and acquisition of specific CTLs (cytotoxic T Lymphocytes) by in-vitro stimulation of CD8+T cells is low in efficiency. The kit hereincomprises an HLA-A2-Ig dimer, an anti-CD28mAb antibody, magnetic beads, and AFP polypeptides. The kit herein is effective in amplifying antigen-specific CTLs in vitro, with specificity maintained formonths; CD*+T cells are stimulated for hepatoma-specific aAPC, the CTLs account for 95% and above the total cell quantity after one week of cultivation, and the amplification times is 1000 and above.The cell quantity can be further increased by repeatedly stimulating the AFP specific CTLs via aAPC. The attained CTLs present effect memory cell features in appearance, and can secrete TNF alpha andIFN gamma.

The invention relates to a kit comprising MHC Class I and Class II HLA-coated beads containing specific antigenic peptides for binding to antigen-specific T cells and the appropriate negative control peptides. Also provided are methods for making the coated beads and methods for use. The application of these beads go to the stimulation of peripheral blood cell populations and in vitro-stimulated culture for the elicitation of functional activities such as cell activation and signaling, cytokine secretion, proliferation and cytotoxicity activity.

A method is provided, including in vitro stimulating an initiating cell population (ICP) of at least 5 million cells that have a density of less than 1.072 g / ml, and at least 1% of which are CD34+CD45− / dim, to differentiate into a progenitor / precursor cell population (PCP). A method is provided, including in vitro stimulating an initiating cell population (ICP) of at least ten thousand cells that have a density of less than 1.072 g / ml to differentiate into a progenitor / precursor cell population (PCP). A method is provided, including separating lower density cells from higher density cells, the lower density cells defining an initiating cell population (ICP), and in vitro stimulating the ICP to differentiate into a progenitor / precursor cell population (PCP). Other embodiments are also described.

The present invention relates to a composition for use as an immunomodulator comprising small molecular weight components of less than 3000 daltons, and having the following properties: a) is extractable from bile of animals; b) is capable of stimulating monocytes and macrophages in vitro; c) is capable of modulating tumor necrosis factor production; d) contains no measurable IL-1a, IL-1b, TNF, IL-6, IL-8, IL-4, GM-CSF or IFN-gamma; e) has an anti-proliferative effect in a malignant mouse hybridoma cell line; f) shows no cytotoxicity to human peripheral blood mononuclear cells; and g) is not an endotoxin. The invention also relates to a method of preparing the composition and its use an immunomodulator.

The invention discloses an EBV (Epstein-Barr Virus) composite antigen, a dendritic cell vaccine and application of the dendritic cell vaccine in preparation of medicines for treating EBV-related infectious diseases, and belongs to the technical field of biological medicines. According to the invention, dendritic cells of a patient are stimulated in vitro, lysates of a plurality of EBV infected cells with superstrong immunogenicity for EBV-related infectious diseases are loaded, and the lysates are induced to mature under the conditions of a plurality of cytokines and specific agonists, so that a complete dendritic cell vaccine with corresponding antigens is formed; after being transfused back to a human body to activate an immune system, cytotoxic T cells are generated, EBV infected cells are killed, an immunological effect is exerted, and the life quality of a patient is improved; the dendritic cell vaccine has a preparation cycle of about 1 week, is short in time, low in cost, safe and almost free of side effects.

The invention relates to the field of biological medicine, and in particular relates to application of pulsatilla saponin B4 to preparation of medicine for preventing and / or treating tumor. Results ofhemolysis tests show that the pulsatilla saponin B4 does not have the obvious hemolysis phenomenon during incitation by in vitro addition in rabbit 2-percent erythrocyte suspension for stimulation. According to the evaluation on toxicity of the pulsatilla saponin B4 to the in vitro cell, the condition that the pulsatilla saponin B4 does not have the obvious cell toxicity to the in vitro culturedRD cells is discovered through study. The acute toxicity tests are used for evaluating the safety of the pulsatilla saponin B4; test results show that the pulsatilla saponin B4 is safe and non-toxic.Through MTT experiments, the condition that the pulsatilla saponin B4 does not have the cell toxic effects on S180 and Lewis cancer cells, and cannot be used for inhibiting the tumor cell multiplication is discovered; but the results of mice in vivo transplantation tumor tests show that the pulsatilla saponin B4 obviously inhibits the growth of the S180 sarcoma growth in the bodies of the mice, and the anti-tumor effect is achieved in the bodies.

The present invention relates to the prevention and treatment of disease like cancer. The inventors have previously characterized MELOE-1 antigen as an IRES dependent, melanoma specific translation product from a lncRNA mainly transcribed in the melanocytic lineage. MELOE-1 contains numerous class II epitopes and one HLA-A*0201-restricted CD8 epitope eliciting a frequent repertoire of high avidity T cells. They designed various synthetic long peptide (SLPs) comprising a CD4 epitope coupled to the CD8 epitope by a serie of linkers of 4 to 6 aa and studied the efficacy of T cell clone activation by SLP-loaded DC in vitro. Particularly, they evaluated the ability of a few selected SLPs to stimulate specific T cells proliferation of PBL from healthy donors in vitro and finally, they explored the vaccination potential of their best SLP candidate in vivo in an HLA*A0201 / HLA-DRB0101 transgenic mouse. Thus, the present invention relates a SLP comprising a CD4 class II peptide linked to a CD8 class I peptide by a specific linker and its use in the treatment of disease like cancers.

The invention relates to a medical suture friction testing apparatus. The apparatus comprises an assembly for testing the friction performance of a medical suture when the medical suture penetrates tissues, and an assembly for testing the friction performance between medical sutures. The assembly for testing the friction performance of a medical suture penetrating tissues stimulates the friction performance between the medical suture and all tissues when the medical suture penetrates human tissues, and the assembly for testing the friction performance between medical sutures stimulates the friction assembly between the medical sutures in the knotting process of the medical suture. The two assemblies can be arranged in a multifunctional fiber strength and elongation tester to replace a lower clamping head of the tester in order to carry out relevant friction performance test. The invention also discloses a corresponding medical suture friction testing method. The friction testing apparatus has the advantages of simple structure, convenient operation, and objective and real result. The apparatus and the method fill up a blank in the quantitative characterization of present in-vitro stimulation of the friction performance of the medical suture, and provide scientific bases for the improvement of the structure of the medical suture.

Disclosed are methods, device kits, and systems for improved quantification of mRNA from whole blood. More particularly, the devices and kites related thereto are useful for the controlled and repeatable ex vivo stimulation of whole blood.